Skip to main content

Table 6 EHR cohort (n = 367): Concomitant medication at index

From: Evaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR study

Treatment n (%)
ASTHMA MEDICATIONS 367 (100.0%)
 Inhaled corticosteroids (ICS) 215 (58.6)
 Long-acting ß2-agonists (LABA) 124 (33.8)
 ICS/LABA combination 208 (56.7)
 Adrenergic in combination with anticholinergics 5 (1.4)
 Short acting 5 (1.4)
 Long acting NA
 Leukotriene modifiers (LTRA) 113 (30.8)
 Methylxanthines 4 (1.1)
 Anti-IgE treatment NA
 Short-acting ß2-agonists (SABA) 256 (69.8)
 Systemic corticosteroids (OCS) 367 (100.0)
 Anticholinergics 21 (5.7)
  - Short acting 9 (2.5)
  - Long acting 13 (3.5)
 Omalizumab NA
 PD4 antagonists NA
 N-acetylcysteine 126 (34.3)
Cardiovascular medications (ANY) 155 (42.2)
 Anti-dyslipidaemias 50 (13.6)
 Statins 48 (13.1)
 Fibrates 1 (0.3)
 Anti-hypertensives 90 (24.5)
 Beta-blockers 47 (12.8)
 ACEs 29 (7.9)
 ARBs 44 (12.0)
Other medications 111 (30.2)
 Antibiotics 169 (46.0)
 Anti-virus 11(3.0)
 Anti-allergy 3 (0.8)
 Cough and cold 223 (60.8)
 Antihistamines 201 (54.8)
 Nasal corticosteroids 162 (44.1)
 Antidepressant 65 (17.7)
 Hypnotics 46 (12.5)
 Antianxiety 63 (17.2)
 Bifosfonates 10 (2.7)
 Calcium D vitamine 2 (0.5)
  1. NA = value not found or zero